← Back to patent-cliff list
CAS 147-71-7
(2S,3S)-(-)-Tartaric acid(2S,3S)-2,3-dihydroxysuccinic acid
Codes: (VII)461018-26-a, LINA-017
Application context (from source-drug indications)
Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinibType 2 diabetesLinagliptin
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ibrutinib | Tier A — Act now | 2027 |
| Linagliptin | Tier C — Watch / trade | 2029 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Azabenzene→3-Pyridylsulfonic acid→3-Hydroxypyridine→3-Hydroxypiperidine→(2S,3S)-4-[(4-Chlorophenyl)amino]-2,3-dihydroxy-4-oxobutanoic acid (3S)-piperidin-3-ol→1-(Phenylmethyl)-3-piperidinol→(2S,3S)-4-((4-Chlorophenyl)amino)-2,3-dihydroxy-4-oxobutanoic acid→(2S,3S)-(-)-Tartaric acid→1-Amino-4-chlorobenzene→(3S)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine
8-bromo-7-(but-2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione→2-(chloromethyl)-4-methylquinazoline→8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione→1-(2-aminophenyl)ethan-1-one→2-chloroacetonitrile→(R)-2-(piperidin-3-yl)isoindoline-1,3-dione (2S,3S)-2,3-dihydroxysuccinate→(R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione→pyridin-3-amine→piperidin-3-amine→isobenzofuran-1,3-dione→2-(piperidin-3-yl)isoindoline-1,3-dione→(2S,3S)-2,3-dihydroxysuccinic acid
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 3-Methylxanthine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 8-Bromo-3-methyl-3,9-dihydro-1H-purine-2,6-dione Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-(Chloromethyl)-4-methylquinazoline Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 8-Bromo-7-(but-2-yn-1-yl)-3-methy1-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | [(3R)-1-[7-(2-Butynyl)-2,3,6,7-tetrahydro-3-methy1-1-[(4-methy1-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yll-3-piperidinyllcarbamicacid 1,1-dimethylethyl ester Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.